NIAID-supported discovery could lead to therapy for deadly illness.

Recent Ebola virus disease (EVD) outbreaks, including the 2013-2016 epidemic that ravaged West Africa and the 2018 outbreak in the Democratic Republic of the Congo, highlight the need for licensed treatments for this often-deadly disease. ZMapp, an experimental therapy comprising three monoclonal antibodies, has shown promise in a clinical trial, but it targets only one of the five known species of Ebola virus. Now, scientists supported by the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health, have discovered a set of powerful, broadly neutralizing antibodies (bNAbs) in the blood of EVD survivors. In animal studies, two of these antibodies provided substantial protection against disease caused by Zaire ebolavirus, Bundibugyo ebolavirus and Sudan ebolavirus, the three species known to cause fatal human illness.

Related posts:

  1. Medicare Card, Study finds Ebola treatment ZMapp holds promise, although results not definitive Medicare Card, Study finds Ebola treatment ZMapp holds promise, although results not definitive...
  2. Led Team Maps Route for Eliciting HIV Neutralizing Antibodies Researchers have traced in detail how certain powerful HIV neutralizing antibodies evolve, a finding that generates vital clues to guide the design of a preventive HIV vaccine, according to a study appearing in Science Express this week. The discoveries were made by a team led by the Vaccine Research Center (VRC) at the National Institute […]...
  3. Medicare Card, NIH scientists map first steps in flu antibody development Medicare Card, NIH scientists map first steps in flu antibody development...
  4. Medicare Card, Experimental chikungunya vaccine induces robust antibody response An experimental vaccine to prevent the mosquito-borne viral illness chikungunya elicited neutralizing antibodies in all 25 adult volunteers who participated in a recent early-stage clinical trial conducted by researchers at the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health. The results are reported in the current issue of […]...
  5. Medicare Card,NIH scientists develop candidate vaccine against respiratory syncytial virus An experimental vaccine to protect against respiratory syncytial virus (RSV), a leading cause of illness and hospitalization among very young children, elicited high levels of RSV-specific antibodies when tested in animals, according to a report in the journal Science....
  6. Antibody treatment protects monkeys from Hendra virus disease A human antibody given to monkeys infected with the deadly Hendra virus completely protected them from disease, according to a study published by National Institutes of Health (NIH) scientists and their collaborators....
  7. Medicare Card, NIH launches human RSV study Medicare Card, NIH launches human RSV study...
  8. Medicare Card, NIH study finds factors that may influence influenza vaccine effectiveness Medicare Card, NIH study finds factors that may influence influenza vaccine effectiveness...
  9. Medicare Card, NIH begins testing investigational Zika vaccine in humans Medicare Card, NIH begins testing investigational Zika vaccine in humans...
  10. Researchers show how anti-HIV drug acts to block herpes virus An anti-HIV drug also discovered to stop the spread of the genital herpes virus does so by disabling a key DNA enzyme of the herpes virus, according to findings by researchers at the National Institutes of Health and other institutions....
  11. Chikungunya vaccine trial begins to enroll participants An experimental vaccine to prevent chikungunya fever, a viral disease spread by certain species of mosquitoes, is being tested in a clinical trial conducted by National Institute of Allergy and Infectious Diseases (NIAID) scientists at the National Institutes of Health....
  12. Medicare Card, NIH launches early-stage yellow fever vaccine trial Yellow fever virus is found in tropical and subtropical, and caused an estimated 29,000 to 60,000 deaths in 2013. The National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health, has begun an early-stage clinical trial of an investigational vaccine designed to protect against yellow fever virus. The Phase 1 […]...
  13. Medicare Card, Stem cell transplants may halt progression of multiple sclerosis Medicare Card, Stem cell transplants may halt progression of multiple sclerosis...
  14. Medicare Medical Care, Rapid Development of Drug-Resistant, 2009 H1N1 Influenza Reported in Two Cases Two people with compromised immune systems who became ill with 2009 H1N1 influenza developed drug-resistant strains of virus after less than two weeks on therapy, report doctors from the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health. Doctors who treat prolonged influenza infection should be aware that even a short course of antiviral treatment may lead to drug-resistant virus, say the authors, and clinicians should consider this possibility as they develop initial treatment strategies for their patients who have impaired immune function....
  15. Medicare Card, Adding chemotherapy following radiation treatment improves survival for adults with a slow-growing type of brain tumor Medicare Card, Adding chemotherapy following radiation treatment improves survival for adults with a slow-growing type of brain tumor...